Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download Microsoft EdgeDownload Microsoft Edge
DBm-Health app

Remote monitoring for patients with, or at risk of diabetes

DBm-Health

Self-monitoring of blood glucose levels

Read Product Guide

DBm-Health is a patient to clinician system that helps health care professionals manage patients with diabetes or at risk of diabetes, and promotes self-care.

It is ideally suited to patients needing additional support to maintain safe blood glucose levels.

The need for safe remote monitoring during the COVID-19 pandemic

The COVID-19 pandemic has increased the need for digital technologies to help clinicians manage their patients remotely, reducing the risk to individuals who are particularly vulnerable to COVID-19 and are advised to shield during the pandemic.

Free smartphone app

Free smartphone app

Patients can input and share blood glucose readings and other relevant data (i.e. medication taken), and request a callback from their care team.

Clinician's desktop app

Patient lists can be filtered to help prioritise interventions; individual blood glucose readings can be viewed; and messages sent to patients via the app or by SMS.

Clinician's desktop app
Self-management for patients

Self-monitoring for patients

Self-help guides and a record of blood glucose readings in diary and graph format helps patients to actively manage their blood glucose levels.

DBm-Health is intended for adult patients with, or at risk of diabetes needing frequent blood glucose monitoring, including:
  • Patients new to insulin treatment needing enhanced diabetes support from their healthcare team
  • Cancer patients receiving high dose steroid treatment
  • Women with diabetes planning a pregnancy
  • Patients with type 1 diabetes not suited to continuous glucose monitoring (CGM)
  • Patients with coronavirus at risk of hyperglycaemia
  • Patients with type 2 diabetes requiring intensive support

Benefits

Increased patient contact
Patient communication

Frequent monitoring of readings and in-app messaging can facilitate improved communication and oversight

Increased service capacity
Increased service capacity

Complex cases can be managed more efficiently, freeing up capacity for more patients without increasing resources

Improved adherence
Improved adherence

Easy-to-use apps can lead to more comprehensive reporting of blood glucose levels

Improved reliability
Improved reliability

Replaces paper-based processes which are associated with poor data reliability

Faster audit
Faster audit

System reports replace time-consuming manual audit processes

Support for self-management
Support for self-monitoring

User-friendly displays of historical readings and self-help guides empower patients to self-manage their condition

DBm-Health is classified as a Medical Device and is registered as such with the UK National Competent Authority (MHRA).

DBm-Health is currently in development phase prior to commercial launch.

Note: Not all Sensyne Health products are available in all territories, for further information contact head office.

FAQs

What is DBm-Health?
Who is DBm-Health intended for?
How do patients access and use the app?
How does the system help healthcare professionals and diabetes services?
How will DBm-Health help the NHS during and after the pandemic?
What are the main features of the app?
How much does DBm-Health cost? 
Does DBm-Health store any patient sensitive data?
What is the background to the development of DBm-Health?
Is there evidence to support the use of digital technologies for the management of blood glucose levels?
Does DBm-Health provide a patient diagnosis? 
Who can see the data entered into DBm-Health? 
What does anonymised data mean?
How do you protect personal and healthcare data? 
Who can patients contact with questions about their data?

References

  1. 2019 surveillance of 4 diabetes guidelines – Consultation document. NICE https://www.nice.org.uk/guidance/ ng28/update/ng28-update-1/documents/surveillance-review-proposal

  2. Kebede MM, Zeeb H, Peters M, Heise TL, Pischke CR. Effectiveness of Digital Interventions for Improving Glycemic Control in Persons with Poorly Controlled Type 2 Diabetes: A Systematic Review, Meta-analysis, and Meta-regression Analysis. Diabetes Technol Ther. 2018;20(11):767-782. doi:10.1089/dia.2018.0216